Publications by authors named "W David Helms"

Claim this Profile
A
Assessing the impact and risk of immunomodulatory compounds on pregnancy.
Joanne Kwak-Kim, Curtis C Maier, Caren M Villano, Christopher J Bowman, Frank R Brennan, Whitney Helms

J Reprod Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, Luckson N Mathieu, Yi Ren, Whitney S Helms

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K Amatya, Whitney S Helms

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With Gene Mutations or Fusions.
Janice Kim, Diana Bradford, Erin Larkins, Lee H Pai-Scherf, Somak Chatterjee, Whitney S Helms

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Denise Casey, Suzanne Demko, Arup Sinha, Pallavi S Mishra-Kalyani, Yuan-Li Shen, Whitney S Helms

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis